Cervical Cancer Treatment Market Segments and Growth by 2031

[Research Report] The cervical cancer treatment market is projected to grow from US$ 10.26 billion in 2024 to US$ 14.91 billion by 2031; the market is anticipated to record a CAGR of 5.7% from 2025 to 2031.

Market Insights and Analyst View:

The cervical cancer treatment market forecast can help stakeholders to plan their growth strategies.

Cervical cancer refers to the cancer that occurs in the cells of the cervix, i.e., the lower part of the uterus that connects to the vagina. In 90% of the cases, cervical malignancies occur due to the HPV infection and are diagnosed through smear screening. The increasing prevalence of cervical cancer and the rise in HPV infections are the key factors driving the cervical cancer treatment market growth. However, the lack of awareness about the diagnosis and treatment methods hampers the growth of the market. Cervical cancer treatment market trends include the increasing R&D for cervical cancer diagnosis and drugs.

Growth Drivers and Challenges:

Increasing Prevalence of Cervical Cancer Fuels Cervical Cancer Treatment Market

Across the globe, cancer is becoming one of the main causes of mortality. According to the World Health Organization (WHO), cancer was the top cause of death for individuals under the age of 70 in 183 nations, while in 123 other countries, it was the fourth most common cause of death globally in 2019. Furthermore, according to the data released by the World Health Organization in March 2021, nearly 10 million fatalities in 2020 were attributed to various forms of cancer. The market under consideration has shown significant expansion, which can be linked to the rising frequency of cervical cancer among women worldwide. According to the World Health Organization (WHO), cervical cancer kills more than 270,000 women each year. Cervical cancer mortality rates are high in poorer nations due to the late discovery of the disease.

The increasing prevalence of cervical cancer has created a burden on the healthcare systems across the world. According to the International Agency for Research on Cancer (IARC), the global burden of new cancer cases is estimated to reach ~27.5 million, and the disease is likely to cause ~163 million deaths by 2040. Factors such as lifestyle changes, smoking, reduced physical activities, and uncertain health and climatic conditions are expected to increase the burden of cancer in the world in the coming years. Therefore, controlling and preventing the increasing number of cancers worldwide is essential.

The lack of awareness about cervical cancer among populations, healthcare providers, and policymakers; limited access to high-quality healthcare services and cervical screening programs; and a lack of functional referral systems are among the factors leading to the high incidence and mortality from cervical cancer. Cervical cancer incidence and mortality have lowered in industrialized countries owing to improved access to cytological screening and rapid treatment of early cervical lesions. It is critical to implement population-based cervical screening and increase its acceptance in low- and middle-income countries (LMICs) to reduce cervical cancer mortality. Raising awareness about risk factors such as first sexual intercourse at a young age and having multiple male sexual partners; the high risk associated with HPV types 8, 9, and 10; first full-term pregnancy at a young age; prolonged use of oral contraceptives; and HIV infections may help boost participation in screening programs. Better awareness regarding the symptoms of cervical cancer, such as intermenstrual vaginal bleeding, postmenopausal vaginal bleeding, post-coital vaginal bleeding, foul vaginal discharge, and lower abdomen pain, might help women seek early help. Thus, the lack of awareness about cervical cancer among populations hinders the cervical cancer treatment market growth.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Cervical Cancer Treatment Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Report Segmentation and Scope:

Segmental Analysis:

Based on type, the market is segmented into squamous cell carcinoma, adenosquamous carcinoma, and adenocarcinoma. The squamous cell carcinoma segment held a larger cervical cancer treatment market share in 2022 and is anticipated to register a higher CAGR during 2022–2030. Based on product, the market is classified as surgery, radiation therapy, chemotherapy, immunotherapy, and therapeutic vaccines. The surgery segment is anticipated to hold a significant share by 2030. In terms of end user, the market is categorized into hospital, homecare, cancer centers, and others. In terms of end user, the hospital segment held the largest cervical cancer treatment market share in 2022. 

Regional Analysis:

In terms of geography, the scope of the cervical cancer treatment market report encompasses North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America held the largest cervical cancer treatment market share in 2022. In North America, the US holds a significant share. Constantly ongoing R&D activities, financial assistance from governments and other public and private organizations, partnerships between IT and pharmaceutical firms, and the rising incidences of neurological diseases primarily drive market growth in the country. Furthermore, strategic initiatives taken by the government to improve the testing procedures are anticipated to benefit the market during the forecast period. The increasing adoption of regulations pertaining to rare diseases will most likely present an opportunity for market expansion. For example, the American Cancer Society (ACS) revised the cervical cancer screening standards in September 2020.

Cervical Cancer Treatment Market Regional Insights

The regional trends and factors influencing the Cervical Cancer Treatment Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Cervical Cancer Treatment Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Cervical Cancer Treatment Market Report Scope

Cervical Cancer Treatment Market Players Density: Understanding Its Impact on Business Dynamics

The Cervical Cancer Treatment Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Cervical Cancer Treatment Market are:

1. F. Hoffmann-La Roche Ltd
2. Merck Sharp
3. Dohme Corp.
4. GlaxoSmithKline plc.
5. Genentech, Inc.
6. Amgen Inc.

Disclaimer: The companies listed above are not ranked in any particular order.

Industry Developments and Future Opportunities:

The cervical cancer treatment market analysis is carried out by identifying and evaluating key players operating in the market. A few initiatives taken by key market players are listed below:

• In January 2024, Pfizer Inc. and Genmab A/S announced that the US Food and Drug Administration (FDA) accepted the supplemental Biologics License Application (sBLA) to convert TIVDAK's (tisotumab vedotin-tftv) approval for the treatment of patients with recurrent or metastatic cervical cancer whose disease progresses on or after first-line therapy. With a Prescription Drug User Fee Act (PDUFA) goal date of May 9, 2024, the application has been awarded Priority Review.
• In September 2023, Guangzhou Gloria Biosciences (GloriaBio) announced that Zimberelimab injection (YuTuo, GLS-010), a fully human anti-PD-1 monoclonal antibody, has been approved for marketing by the China National Medical Products Administration (NMPA). The injection can be used as a monotherapy to treat patients with recurrent or metastatic cervical cancer (R/M CC). The third immune checkpoint inhibitor (ICI) antibody approved worldwide for treating cervical cancer is zimberelimab—the first and only one authorized in China.

Competitive Landscape and Key Companies:

F. Hoffmann-La Roche Ltd, Merck Sharp, Dohme Corp., GlaxoSmithKline plc., Genentech Inc., Amgen Inc., Advaxis Inc., Biocon, Allergan Inc., Pfizer Inc., and AstraZeneca are a few key companies profiled in the cervical cancer treatment market report. These companies focus on expanding their offerings to meet the growing consumer demand worldwide. Their global presence allows them to serve many customers, subsequently allowing them to expand their market presence.